LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Rees, Frances; Doherty, Michael; Grainge, Matthew; Lanyon, Peter; Davenport, Graham; Zhang, Weiya (2016)
Publisher: Wiley
Languages: English
Types: Article
Subjects: RA
Objective: To estimate the comorbidity associated with systemic lupus erythematosus (SLE) in the UK during 1999–2012. \ud \ud Methods: A retrospective cohort study using the UK Clinical Practice Research Datalink was conducted. Prevalent cases of SLE were matched by age, sex, and practice to 4 controls. The incidence of cardiovascular disease (CVD), stroke, end-stage renal failure (ESRF), cancer, osteoporosis, and infection were calculated per 1,000 person-years during the study period and compared to controls using Poisson regression to obtain incidence rate ratios (IRRs). IRRs were adjusted for baseline age, sex, body mass index, smoking status, alcohol intake, hypertension, hyperlipidemia, Charlson Index scores, and prednisolone use. Age- and sex-specific incidence rates were calculated. \ud \ud Results: When comparing the 7,732 prevalent cases of SLE with 28,079 matched controls, the unadjusted IRR was 1.98 (95% confidence interval [95% CI] 1.69–2.31) for CVD, 1.81 (95% CI 1.49–2.19) for stroke, 7.81 (95% CI 4.68–13.05) for ESRF, 1.28 (95% CI 1.17–1.40) for cancer, 2.53 (95% CI 2.27–2.82) for osteoporosis, and 1.49 (95% CI 1.40–1.58) for infection. After adjustment, the rates remained significantly higher in cases. Men with SLE had higher rates of CVD, stroke, and cancer, whereas women had higher rates of infection and osteoporosis. Those at younger ages were at the greatest relative risk compared with controls. Cases had significantly higher Charlson Index scores at baseline. \ud \ud Conclusion: People with SLE in the UK have a greater burden of comorbidity and are more likely to develop CVD, stroke, ESRF, cancer, osteoporosis, and infection than people of the same age and sex.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Lim SS, Bayakly AR, Helmick CG, Gordon C, Easley KA, Drenkard C. The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheum 2014;66:357-68.
    • 2. Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, et al. Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. Arthritis Rheum 2014;66:369-78.
    • 11. Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 2005;64:111-3.
    • 12. Almehed K, Forsblad d EH, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients - Extended report. Rheumatology (Oxford) 2007;46:1185-90.
    • 13. Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: Hospitalisations and mortality. Lupus 2009;18 682-89.
    • 14. Gladman DD, Hussain F, Ibanez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002;11:234-39.
    • 15. Bosch X, Guilabert A, Pallares L, Cervera R, Ramos-Casals M, Bove A, et al. Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients. Lupus 2006;15:584-89.
    • 16. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
    • 17. Bengtsson C, Ohman ML, Nived O, Dahlqvist SR. Cardiovascular event in systemic lupus erythematosus in northern Sweden: Incidence and predictors in a 7-year follow-up study. Lupus 2012;21 452-59.
    • 18. Gordon C. Long-term complications of systemic lupus erythematosus. Rheumatology (Oxford) 2002;41:1095-100.
    • 19. Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C. Lupus and cancer. Lupus 2009;18:479-85.
    • IR of co-morbidity, per 1,000 person-years (95% CI) in controls 5.46 (4.67 6.39) 2.16 (1.96 2.39) Incidence rate, per 1,000 person-years (95% CI) 0.81 2.27 1.63 1.72 2.27 1.05) 0.85 1.13) 7.54) 1.37 5.74) 3.50) 1.86 4.22) 3.45) 1.28 2.80) 6.65) 1.04 3.64)
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok